Vanda Pharmaceuticals Inc. followed up its Phase III success late last year with the schizophrenia tablet iloperidone by submitting a new drug application to the FDA. The company is using a personalized-medicine approach, partly to ensure the compound's efficacy and partly to quell any potential safety concerns - namely, problems with prolonged QT intervals, a common bugaboo in the class. (BioWorld Today) Read More
